News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fortimedix Surgical Announces Data Demonstrating Feasibility Of symphonX Based Surgical Platform For Transanal Colon Resection (TaCR)



7/19/2017 11:07:19 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

NUTH, The Netherlands and SAN DIEGO, July 19, 2017 (GLOBE NEWSWIRE) -- Fortimedix Surgical today announced cadaver case series results demonstrating feasibility of a symphonX™ based surgical platform for transanal colon resection (TaCR), also presented last week at the American Society For Gastrointestinal Endoscopy (ASGE) NOSCAR Summit in Downers Grove, IL.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/800572bd-c676-4d40-a7ba-972241234de0

The studies (n=5) were performed in 2016 and 2017 by internationally renowned surgeon Dr. Karl-Hermann Fuchs, who serves on the company’s Scientific Advisory Board. The results demonstrate that further reduction of abdominal trocars and operative trauma during transanal colon resection is possible and that pure TaCR using a modified version of the symphonX™ surgical platform seems feasible. The data also reveals a promising learning curve, suggesting that clinicians are able to learn the technique of using this platform quickly. symphonX™ is the world’s smallest single-port surgery solution for use in minimally invasive abdominal laparoscopic surgery.

“When performing transanal colon resection, it is important to have the right tools that provide sufficient range of motion to reach target anatomies with ease and achieve excellent triangulation for optimal tissue manipulation, retraction and exposure,” said Dr. Karl-Hermann Fuchs, Chief of Surgery at Agaplesion Markus Hospital, Frankfurt am Main. “These cadaver studies show that the symphonX™ based platform enables transanal colon resection with the aid of only a single 5mm transabdominal trocar for visualization. This is an important result that could have positive effects on patient outcomes in terms of post-operative pain, wound complications and hernia development following surgery. We are optimistic that further studies will confirm this finding. The next step will be an in vivo surgery with this modified symphonX™ platform.”

The results of the studies were also presented at the 25th International Congress of the European Association for Endoscopic Surgery (EAES) in Frankfurt am Main by Dr. Hans F. Fuchs last month.

For additional information visit www.fortimedixsurgical.com

About symphonX™
symphonX™ is the world’s first single-port surgery solution compatible with a standard 15mm laparoscopic trocar. Emulating conventional, multi-port laparoscopy makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach. symphonX™ is poised to deliver on the promise of single-port surgery, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis, elevating the standard of care in laparoscopy.

About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 18 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
For more information, please visit www.fortimedixsurgical.com

Forward-Looking Statements
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.


For media inquiries, please contact: Fortimedix Surgical B.V., Monique Biermans, m.biermans@fortimedix.com, +31 (0)6 24 676 376 Digital press release available at: www.fortimedixsurgical.com/news-events/news-events Lazar Partners, Chantal Beaudry, cbeaudry@lazarpartners.com, or Amy Feldman, afeldman@lazarpartners.com, +1 (212) 867-1762

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES